Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Signs $267 Million Deal for Novel Anti-Inflammatory Candidate

publication date: Sep 28, 2021

Suzhou Innovent Bio acquired China rights to an atopic dermatitis therapy developed by Denmark's Union Therapeutics in a $267 million agreement. Innovent will pay $20 million upfront and make up to $247 million in milestones, plus royalties. The candidate, orismilast, is a next-gen PDE4 inhibitor with broad anti-inflammatory properties that has shown positive proof of concept data orally in psoriasis and topically in atopic dermatitis. Orismilast is being developed as a best- or first-in-class treatment option in both diseases. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here